Evestra, Inc.

10 patents currently held · Updated Nov 14, 2026

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Ending by 2030

Jan 2031

Next term end

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

1 fee due Feb 4, 2027
The maintenance fee for Imidazolyl progesterone antagonists (US 9,096,641) comes due Feb 4, 2027. Unpaid by Aug 4, 2027, it lapses early.
1 fee due Oct 21, 2027
The maintenance fee for Longer-acting progestin prodrug contraceptives (US 10,624,903) comes due Oct 21, 2027. Unpaid by Apr 21, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

1 of the patents on this record was granted since Aug 16, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Showing 1 to 10 of 10

Patent	Title	Status	Expires	Confidence
US 8,222,237	Progestational 3-(6,6-ethylene-17B-hydroxy-3-oxo-17A-pregna-4-ene-17A-yl)propionic acid G-lactones In force Term ends Jan 27, 2031 · From the USPTO record	In force	Term ends Jan 27, 2031	From the USPTO record
US 8,673,968	Progesterone antagonists In force Term ends Mar 23, 2031 · From the USPTO record	In force	Term ends Mar 23, 2031	From the USPTO record
US 9,096,641	Imidazolyl progesterone antagonists In force Term ends Jun 22, 2033 · From the USPTO record	In force	Term ends Jun 22, 2033	From the USPTO record
US 10,273,263	Pro-Drug Forming Compounds In force Ends no later than Jul 11, 2034 · Low confidence	In force	Ends no later than Jul 11, 2034	Low confidence
US 9,745,338	Pro-drug forming compounds In force Term ends Jul 20, 2034 · From the USPTO record	In force	Term ends Jul 20, 2034	From the USPTO record
US 9,850,273	Combination of estrogens plus antiprogestins with significant partial agonistic effect as an effective treatment of menopausal symptoms and for prevention of the occurrence of breast cancer In force Term ends Dec 3, 2035 · From the USPTO record	In force	Term ends Dec 3, 2035	From the USPTO record
US 10,053,485	Cytotoxic agents that preferentially target leukemia inhibitory factor (LIF) for the treatment of malignancies and as new contraceptive agents In force Term ends Mar 22, 2036 · From the USPTO record	In force	Term ends Mar 22, 2036	From the USPTO record
US 10,738,075	Cytotoxic agents that preferentially target leukemia inhibitory factor (LIF) for the treatment of malignancies and as new contraceptive agents In force Term ends Mar 22, 2036 · From the USPTO record	In force	Term ends Mar 22, 2036	From the USPTO record
US 10,624,903	Longer-acting progestin prodrug contraceptives In force Term ends Sep 14, 2038 · From the USPTO record	In force	Term ends Sep 14, 2038	From the USPTO record
US 12,747,263	Orally Active Leukemia Inhibitory Factor (LIF) Antagonists for the Treatment of Cancer In force Term ends Feb 8, 2043 · High confidence	In force	Term ends Feb 8, 2043	High confidence

Also on record, not counted in the 10: 2 lapsed for an unpaid fee. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

8 no status recorded

List them